首页> 美国卫生研究院文献>The Journal of Clinical Investigation >Identification of a lymphocyte surface receptor for low density lipoprotein inhibitor an immunoregulatory species of normal human serum low density lipoprotein.
【2h】

Identification of a lymphocyte surface receptor for low density lipoprotein inhibitor an immunoregulatory species of normal human serum low density lipoprotein.

机译:鉴定低密度脂蛋白抑制剂的淋巴细胞表面受体低密度脂蛋白抑制剂是正常人血清低密度脂蛋白的免疫调节物质。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study demonstrates the existence on human peripheral blood lymphocytes of a saturable cell surface receptor for low density lipoprotein inhibitor (LDL-In), a subset of normal human serum low density lipoprotein (LDL) that has been previously demonstrated to suppress selected lymphocyte functions in vivo and in vitro. The binding of radioiodinated LDL-In of demonstrable biological activity occurs rapidly and is quantitatively augmented by prior cultivation of the lymphocytes in lipoprotein-depleted serum, suggesting regulation of receptor density by lipoproteins in vivo. Binding is temperature dependent, facilitated by calcium ions, saturable at 4 degrees C within 40-60 min, and blocked by prior exposure to unlabeled LDL-In. The lymphocyte receptor is trypsin sensitive and regenerates in vitro with a t1/2 of 3.6 h. LDL-In receptors are calculated to have a maximum density of 4,860 +/- 460 per cell if uniformly distributed on all lymphocyte subsets. These receptors have an estimated average association constant of 1.47 X 10(7) liters/mol. When considered in context of the estimated concentration of LDL-In in blood, the receptors should be partially occupied in vivo by endogenous plasma LDL-In. Prior site occupancy inhibition experiments designed to analyze the specificity of LDL-In binding demonstrate that (a) LDL-In is 13.7-fold more effective than whole LDL in blocking the subsequent binding of 125I-LDL-In to cells; and that (b) LDL is 11-fold more effective than LDL-In in blocking the binding of 125I-LKL. This is consistent with the degree of contamination of each lipoprotein with the other lipoprotein. An independent identity of the LDL-In receptor is also supported by observations that in contrast to the previously described LDL receptor, synthesis and expression of the LDL-In receptor on lymphocytes are not suppressed by cultivation of the cells in the presence of 25-hydroxycholesterol and cholesterol. These findings suggest the existence of a previously undescribed and discrete receptor on lymphocytes for LDL-In, and that the modulation of lymphocyte function by LDL-In may be mediated by a specific cell surface receptor pathway.
机译:本研究表明低密度脂蛋白抑制剂(LDL-In)可饱和细胞表面受体存在于人外周血淋巴细胞上,低密度脂蛋白抑制剂是正常人血清低密度脂蛋白(LDL)的子集,先前已被证实可抑制选定的淋巴细胞功能体内和体外。具有可证明的生物学活性的放射性碘化的LDL-In的结合迅速发生,并且通过在贫脂蛋白的血清中预先培养淋巴细胞而定量地增加了其结合,表明体内脂蛋白对受体密度的调节。结合是温度依赖性的,由钙离子促进,在40°C到40°C的饱和度在40-60分钟内饱和,并通过事先暴露于未标记的LDL-In来阻断。淋巴细胞受体对胰蛋白酶敏感,并在体外以3.6小时的t1 / 2再生。如果LDL-In受体均匀分布在所有淋巴细胞亚群上,则每个细胞的最大密度为4,860 +/- 460。这些受体的平均缔合常数估计为1.47 X 10(7)升/摩尔。当考虑到血液中LDL-In的估计浓度时,受体应在体内被内源性血浆LDL-In部分占据。旨在分析LDL-In结合特异性的先前位点占用抑制实验表明:(a)LDL-In在阻止125I-LDL-In与细胞的后续结合方面比整个LDL有效13.7倍; (b)LDL在阻断125I-LKL结合方面比LDL-In高11倍。这与每个脂蛋白被另一个脂蛋白的污染程度一致。与先前描述的LDL受体相反,通过观察在25-羟基胆固醇存在下细胞的培养,LDL-In受体的合成和表达不受抑制,这也支持了LDL-In受体的独立身份。和胆固醇。这些发现表明LDL-In的淋巴细胞上存在先前未描述的离散受体,并且LDL-In对淋巴细胞功能的调节可能由特定的细胞表面受体途径介导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号